Review of Newer Antifungal and Immunomodulatory Strategies for Invasive Aspergillosis

Clinical Infectious Diseases

Volumn 37, Issue SUPPL. 3, 2003, Pages

  Steinbach, William J ^a,d   Stevens, David A ^b,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CALIFORNIA INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 (4 CHLOROPHENYL) 2 PROPENOYL] 4 [2 (4 CHLOROPHENYL)VINYL] 1 ETHYL 4 PIPERIDINOL; ALLYLAMINE DERIVATIVE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; COLONY STIMULATING FACTOR 1; GAMMA INTERFERON; INTERLEUKIN 10 ANTIBODY; ITRACONAZOLE; KETONE DERIVATIVE; MICAFUNGIN; NIKKOMYCIN; NIKKOMYCIN Z; NYSTATIN; PHENYTOIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PRISTINAMYCIN; PYRROLE DERIVATIVE; RAVUCONAZOLE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SORDARIN DERIVATIVE; TERBINAFINE; TUMOR NECROSIS FACTOR ALPHA; VORICONAZOLE; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; CYTOKINE; POLYENE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL THERAPY; ASPERGILLOSIS; CLINICAL TRIAL; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; EPILEPSY; GRANULOCYTE TRANSFUSION; HAIR LOSS; HEPATITIS; HUMAN; IMMUNOTHERAPY; KIDNEY DISEASE; NEPHROTOXICITY; NONHUMAN; PANCYTOPENIA; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; VISUAL DISORDER; CHEMISTRY; CLASSIFICATION; DRUG COMBINATION; GRANULOCYTE; IMMUNOLOGY; MICROBIOLOGICAL EXAMINATION;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; AZOLES; CHEMISTRY, PHARMACEUTICAL; CYTOKINES; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; GRANULOCYTES; HUMANS; IMMUNOTHERAPY; MICROBIAL SENSITIVITY TESTS; POLYENES;

EID: 0141956267     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/376523     Document Type: Review

References (391)

1. Groll AH, Shah PM, Mentzel C, et al. Trends in postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33:23-32.
2. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis 2000; 31:1524-8.
3. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26:781-805.
4. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23:608-15.
5. Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. J Infect 1998; 37:173-80.
6. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of all published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003; 37(Suppl 3):S188-224 (in this issue).
7. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30:696-709.
8. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79:250-60.
9. Meis JFM, Verweij PE. Current management of fungal infections. Drugs 2001; 61:13-25.
10. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activity of azoles. Antimicrob Agents Chemother 1998; 42: 3018-21.
11. Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother 1990; 34:183-8.
12. Walsh TJ, Viviani MA, Arathoon E, et al. New targets and delivery systems for antifungal therapy. Med Mycol 2000; 38:335-47.
13. De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001; 61:27-37.
14. Ernst EJ. Investigational antifungal agents. Pharmacotherapy 2001; 21:165S-75S.
15. Graybill JR. The echinocandins, first novel class of antifungals in two decades: will they live up to their promise? Int J Clin Pract 2001; 55: 633-8.
16. Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41:2326-32.
17. Kurtz MB, Douglas CM. Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol 1997; 35:79-86.
18. Groll AH, Piscitelli SC, Walsh TJ. Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy 2001; 21:133S-48S.
19. Kontoyiannis DP. A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. Pharmacotherapy 2001; 21:175S-87S.
20. Benz F, Knuessel F, Nuesch J, et al. Echinocandin B, ein neuartiges polypeptid antibioticum aus Aspergillus nidulans var echinulatus: isolierung and baudsteine. Helv Chim Acta 1974; 57:2459-77.
21. Denning DW, Stevens DA. Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 1991; 35:1329-33.
22. Arathoon E. Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis 2001; 14:685-91.
23. Petranyi G, Ryder NS, Stutz A. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 1984; 224:1239-41.
24. Katz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol 1999; 141:26-32.
25. Perez A. Terbinafine: broad new spectrum of indications in several subcutaneous and systemic and parasitic diseases. Mycoses 1999; 42: 111-4.
26. Ryder NS, Leitner I. In vitro activity of terbinafine (lamisil): an update. J Dermatolog Treat 1998; 9:S23-8.
27. Obi K, Uda JI, Iwase K, Sugimoto O, Ebisu H, Matsuda A. Novel nikkomycin analogues: inhibitors of the fungal cell wall biosynthesis enzyme chitin synthase. Bioorg Med Chem Lett 2000; 10:1451-4.
28. Li RK, Rinaldi MG. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob Agents Chemother 1999; 43:1401-5.
29. Dahn U, Hagenmaier H, Hohne H, Konig WA, Wolf G, Zahner H. Stoffweschselprodukte von mikroorganismen. 154. Mitteilung. Nikkomycin, ein neuer hemmstoff der chitin-synthese bei pilzen. Arch Microbiol 1976; 107:143-60.
30. Hector RF. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993; 6:1-21.
31. Hector RF, Zimmer BL, Pappagianis D. Inhibitors of cell wall synthesis: nikkomycins. In: Yamaguchi H, ed. Recent progress in antifungal chemotherapy. New York: Marcel Dekker, 1991:341-53.
32. Stevens DA. Drug interaction studies of a glucan synthase inhibitor (LY303366) and a chitin synthase inhibitor (nikkomycin Z) for inhibition and killing of fungal pathogens. Antimicrob Agents Chemother 2000; 44:2547-8.
33. Dominguez JM, Kelly VA, Kinsman OS, Marriott MS, Gomez de las Heras F, Martin JJ. Sordarins: a new class of antifungal with selective inhibition of the protein synthesis elongation cycle in yeast. Antimicrob Agents Chemother 1998; 42:2274-8.
34. Cuevas JC, Lavandera JL, Martos JL. Design and synthesis of simplified sordaricin derivatives as inhibitors of fungal protein synthesis. Bioorg Med Chem Lett 1999; 9:103-8.
35. Herreros E, Martinez CM, Almela MJ, Marriott MS, Gomez de las Heras F, Gargallo-Viola D. Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi. Antimicrob Agents Chemother 1998; 42: 2863-9.
36. Martinez A, Aviles P, Jimenez E, Caballero J, Gargallo-Viola D. Activities of sordarins in experimental models of candidiasis, aspergillosis, and pneumocystosis. Antimicrob Agents Chemother 2000; 44: 3389-94.
37. Manavathu EK, Dimmock JR, Vashishtha SC, Cutright J, Chandrasekar PH. In-vitro and in-vivo susceptibility of Aspergillus fumigatus to a novel conjugated styryl ketone. J Antimicrob Chemother 1998; 42:585-90.
38. Luna T, Mazzolla R, Romano G, Blasi E. Potent antifungal effects of a new derivative of partricin A in a murine model of cerebral cryptococcosis. Antimicrob Agents Chemother 1997; 41:706-8.
39. Strippoli V, Simonetti N, D'Auria FD, Bruzzese T. In vivo activity of SPA-S-753, a water soluble polyene antibiotic effective against C. albicans. European Bulletin of Drug Research 1994; 3:71-6.
40. Strippoli V, D'Auria FD, Simonetti N, Basti D, Bruzzese T. In vivo and in vitro antifungal activity of the polyene derivative SPA-S-753 against encapsulated form of Cryptococcus neoformans. Infection 1997; 25:27-31.
41. Clemons KV, Stevens DA. Efficacy of the partricin derivative SPA-S-753 against systemic murine candidosis. J Antimicrob Chemother 2001; 47:183-6.
42. Rimaroli C, Bruzzese T. Overview of SPA-S-843 in vitro activity against filamentous fungi. Chemotherapy 2000; 46:28-35.
43. Walsh TJ, Giri N. Pradimicins: a novel class of broad-spectrum antifungal compounds. Eur J Clin Microbiol Infect Dis 1997; 16:93-7.
44. Gonzalez CE, Groll AH, Giri N, et al. Antifungal activity of the pradimicin derivative BMS 181184 in the treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998; 42:2399-404.
45. Espinel-Ingroff A, Warnock DW, Vazquez A, Arthington-Skaggs BA. In vitro antifungal susceptibility methods and clinical implications of antifungal resistance. Med Mycol 2000; 38:293-304.
46. Cormican MG, Pfaller MA. Standardization of antifungal susceptibility testing. J Antimicrob Chemother 1996; 38:561-78.
47. Johnson EM, Oakley KL, Radford SA, et al. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother 2000; 45: 85-93.
48. Lass-Florl C, Kofler G, Kropshofer G, et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 1998; 42:497-502.
49. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997; 40:401-14.
50. Denning DW, Venkateswarlu K, Oakley KL, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41:1364-8.
51. Dannaoui E, Persat F, Monier MF, Borel E, Peins MA, Picot S. In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole. J Antimicrob Chemother 1999; 44:553-5.
52. Chryssanthou E. In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. Acquired resistance to itraconazole. Scand J Infect Dis 1997; 29:509-12.
53. Chandrasekar PH, Cutright JL, Manavathu EK. Aspergillus: rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999. Diagn Microbiol Infect Dis 2001; 41:211-4.
54. Varanasi NL, Manavathu EK, Baskaran I, Alangaden GJ, Thomas PA, Chandrasekar PH. In vitro susceptibility and azole resistance among clinical and laboratory-selected isolates of Aspergillus flavus obtained from three continents [abstract J-271]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
55. Mosquera J, Denning DW. Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2002; 46:556-7.
56. Espinel-Ingroff A, Dawson K, Pfaller M, et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995; 39:314-9.
57. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi: proposed standard [NCCLS document M38-P]. Wayne, PA: National Committee for Clinical Laboratory Standards, 1998.
58. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard [NCCLS document M38-A]. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
59. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast: approved standard. NCCLS document M27-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 1997.
60. Llop C, Pujol I, Aguilar C, Sala J, Riba D, Guarro J. Comparison of three methods of determining MICs for filamentous fungi using different end point criteria for incubation periods. Antimicrob Agents Chemother 2000; 44:239-42.
61. Pfaller MA, Messer SA, Mills K, Bolmstrom A. In vitro susceptibility testing of filamentous fungi: comparison of E-test and reference microdilution methods for determining itraconazole MICs. J Clin Microbiol 2000; 38:3359-61.
62. Dupont B, Richardson M, Verweij PE, Meis JFGM. Invasive aspergillosis. Med Mycol 2000; 38:215-24.
63. Kurtz MB, Heath IB, Marrinan J, Dreikorn S, Douglas C. Morphological effects of pneumocandins against Aspergillus fumigatus correlate with activity against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994; 38:1480-9.
64. Oakley KL, Moore CB, Denning DW. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother 1997; 41: 1124-6.
65. Kullberg BJ, de Pauw BE. Therapy of invasive fungal infections. Neth J Med 1999; 55:118-27.
66. Warnock DW. Amphotericin B: an introduction. J Antimicrob Chemother 1991; 28:27-38.
67. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12:308-29.
68. Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999; 12:310-50.
69. Luna B, Drew RH, Perfect JR. Agents for treatment of invasive fungal infections. Otolaryngol Clin North Am 2000; 33:277-99.
70. Atkinson AJ Jr, Bennett JE. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 1978; 13:271-6.
71. Christensen KJ, Bernard EM, Gold JWM, Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis 1985; 152: 1037-43.
72. Ellis M. Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections? Transpl Infect Dis 2000; 2:51-61.
73. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990; 12:1147-200.
74. de Pauw BE. New antifungal agents and preparations. Int J Antimicrob Agents 2000; 16:147-50.
75. Paterson DL, Singh N. Interactions between tacrolimus and antimicrobial agents. Clin Infect Dis 1997; 25:1430-40.
76. Finquelievich JL, Odds FC, Queiroz-Telles F, Wheat LJ. New advances in antifungal treatment. Med Mycol 2000; 38:317-22.
77. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26:1383-96.
78. Llanos A, Cieza J, Bernardo J, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991; 40:302-8.
79. Dismukes WE. Introduction to antifungal agents. Clin Infect Dis 2000; 30:653-7.
80. Proffitt RT, Satorius A, Chiang SM, Sullivan L, Adler-Moore JP. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 1991; 28:49-61.
81. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis 1998; 27:603-18.
82. Brajtburg J, Bolard J. Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev 1996; 9:512-31.
83. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: Recent progress and future directions. Clin Infect Dis 1996; 22:S133-44.
84. Ralph ED, Khazindar AM, Barber KR, Grant CWM. Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves. Antimicrob Agents Chemother 1991; 35: 188-91.
85. Luke RG, Boyle JA. Renal effects of amphotericin B lipid complex. Am J Kidney Dis 1998; 31:780-5.
86. Fielding RM, Smith PC, Wang LH, Porter J, Guo LS. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother 1991; 35:1208-13.
87. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45:3487-96.
88. Gavalda J, Lopez P, Martin MT, Gomis X, Ramirez JL, Pahissa A. High loading doses of liposomal amphotericin B in the treatment of experimental pulmonary aspergillosis [abstract M-189]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
89. Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998; 27:1406-12.
90. Schmitt HJ. New methods of delivery of amphotericin B. Clin Infect Dis 1993; 17:S501-6.
91. Wasan KM, Rosenblum MG, Cheung L, Lopez-Berestein G. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother 1994; 38:223-7.
92. Clark JM, Whitney RR, Olsen SJ, et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991; 35:615-21.
93. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995; 21:1145-53.
94. Bowden RA, Cays M, Gooley T, Mamelok RD, Van Burik J. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after bone marrow transplant. J Infect Dis 1996; 173:1208-15.
95. Graybill JR, Tollemar J, Torres-Rodriguez JM, Walsh TJ, Roilides E, Farmaki E. Antifungal compounds: controversies, queries and conclusions. Med Mycol 2000; 38:323-33.
96. Ringden O, Jonsson V, Hansen M, Tollemar J, Jacobsen N. Severe and common side-effects of amphotericin B lipid complex (Abelcet). Bone Marrow Transplant 1998; 22:733-4.
97. Dix SP, Andriole VT. Lipid formulations of amphotericin B. Curr Clin Top Infect Dis 2000; 20:1-23.
98. Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 1995; 38:459-65.
99. Leenders ACAP, Daenen S, Jansen RLH, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998; 103:205-12.
100. White MH, Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion versus amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997; 24:635-42.
101. van Etten EWM, Stearne-Cullen LET, Ten Kate MT, Bakker-Woudenberg IAJM. Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats. Antimicrob Agents Chemother 2000; 44:540-5.
102. Otsubo T, Maruyama K, Maesaki S, et al. Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice. Antimicrob Agents Chemother 1998; 42:40-4.
103. Saxena S, Khan JA, Ghosh PC. Toxicity and therapeutic efficacy of amphotericin B delivered through cholesterol hemisuccinate vesicles in the treatment of experimental murine aspergillosis. J Antimicrob Chemother 1998; 42:635-42.
104. Clemons KV, Ranney DF, Stevens DA. A novel heparin-coated hydrophilic preparation of amphotericin B hydrosomes. Curr Opin Investig Drugs 2001; 2:480-7.
105. Clemons KV, Ranney DF, Stevens DA. Amphotericin B hydrosomes selective site localization and accumulation, putative binding mechanism, and enhanced pharmacokinetics and clearance [abstract 7.5]. In: Program and abstracts of the 12th Congress of the International Society of Human and Animal Mycology (Adelaide, Australia). International Society of Human and Animal Mycology, 1994.
106. Kilburn KH. The innocuousness and possible therapeutic use of aerosol amphotericin B. Am Rev Respir Dis 1959; 80:441-2.
107. Roth C, Gebhart J, Just-Neubling G, von Eisenhart-Rothe B, Beinhauer-Reeb I. Characterization of amphotericin B aerosols for inhalation treatment of pulmonary aspergillosis. Infection 1996; 24: 354-60.
108. Niki Y, Bernard EM, Schmitt HJ, Tong WP, Edwards FF, Armstrong D. Pharmacokinetics of aerosol amphotericin B in rats. Antimicrob Agents Chemother 1990; 34:29-32.
109. Ruijgrok EJ, Vulto AG, van Etten EWM. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats. J Pharm Pharmacol 2000; 52:619-27.
110. Dubois J, Bartter T, Gryn J, Pratter MR. The physiologic effects of inhaled amphotericin B. Chest 1995; 108:750-3.
111. Cross CE. amphotericin B aerosol for transiently immunocompromised hosts: reasonably safe, but does it matter? Chest 1995; 108: 599-601.
112. Schmitt H, Bernard E, Hauser M, Armstrong D. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1988; 32:1676-9.
113. Ruijgrok EJ, Vulto AG, Van Etten EWM. Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J Antimicrob Chemother 2001; 48:89-95.
114. Ruffini E, Baldi S, Libertucci D, et al. Aerosolized liposomal amphotericin B: a novel and effective treatment for Aspergillus infections in lung transplant recipients [abstract M-1237]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
115. Veltri A, Anselmetti GC, Bartoli G, et al. Percutaneous treatment with amphotericin B of mycotic lung lesions from invasive aspergillosis: results in 10 immunocompromised patients. Eur Radiol 2000; 10: 1939-14.
116. Hazen EL, Brown R. Two antifungal agents produced by a soil actinomycete. Science 1950; 112:423.
117. Andriole VT. Current and future antifungal therapy: new targets for antifungal agents. J Antimicrob Chemother 1999; 44:151-62.
118. Arikan S, Rex JH, Nystatin LF (Aronex/Abbott). Curr Opin Investig Drugs 2001; 2:488-95.
119. Mehta RT, L HR, Gunner LA, Juliano RL, Lopez-Berestein G. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob Agents Chemother 1987; 31:1897-900.
120. Mehta RT, Hopfer RL, McQueen T, Juliano RL, Lopez-Berestein G. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob Agents Chemother 1987; 31:1901-3.
121. Carrillo-Munoz AJ, Quindos G, Tur C, et al. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. J Antimicrob Chemother 1999; 44:397-401.
122. Thomas AH. Suggested mechanisms for the antimycotic activity of the polyene antibiotics and the N-substituted imidazoles. J Antimicrob Chemother 1986; 17:269-79.
123. Groll AH, Gonzalez CE, Giri N, et al. Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics. J Antimicrob Chemother 1999; 43:95-103.
124. Johnson EM, Ojwang JO, Szekely A, Wallace TL, Warnock DW. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother 1998; 42:1412-6.
125. Quindos G, Carrillo-Munoz AJ, Ruesga MT, et al. In vitro activity of a new liposomal nystatin formulation against opportunistic fungal pathogens. Eur J Clin Microbiol Infect Dis 2000; 19:645-8.
126. Oakley KL, Moore CB, Denning DW. Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother 1999; 43:1264-6.
127. Stevens DA. MIC comparisons of six polyene preparations [abstract 9]. In: Program and abstracts of the Focus on Fungal Infections 9 (San Diego). Alpharetta, GA: Imedex, 1999.
128. Wallace T, Carrillo-Munoz A, Denning D, et al. In vitro antifungal activity of Nyotran against clinical isolates [abstract 408]. In: Program and abstracts of the 14th Congress International Society of Human and Animal Mycology, (Buenos Aires). International Society of Human and Animal Mycology, 2000.
129. Wallace TL, Paetznick V, Cossum PA, Lopez-Berestein G, Rex JH, Anaissie E. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob Agents Chemother 1997; 41:2238-43.
130. Denning DW, Warn P. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B. Antimicrob Agents Chemother 1999; 43:2592-9.
131. Krupova Y, Mistrik M, Bojtarova E, Sejnova D, Ilavska I, Krcmery V Jr. Liposomal nystatin (L-NYS) in therapy of pulmonary aspergillosis refractory to conventional amphotericin B in cancer patients. Support Care Cancer 2001; 9:209-10.
132. Offner FCJ, Herbrecht R, Engelhard D, et al. EORTC-IFCG phase II study on liposomal nystatin in patients with invasive aspergillus infections, refractory or intolerant to conventional/lipid ampho B [abstract J-1102]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000.
133. Borgers M, Van de Ven MA, Willemsens G, Van den Bossche H. Morphologic evaluation of R 51211, a new antimycotic (part 61, SE 48/2-13). In: Program and abstracts of the 13th Annual International Congress on Chemotherapy (Vienna). International Society of Chemotherapy, 1983.
134. Van Cutsem J, Van Gerven F, Van de Ven MA, Borgers M, Janssen PAJ. Itraconazole, a new triazole that is orally active against Aspergillus. Antimicrob Agents Chemother 1984; 26:527-34.
135. Heykants J, Van de Valde V, Van Rooy P. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32:67-87.
136. de Repentigny L, Ratelle J, Leclerc JM, et al. Repeated-dose pharmacokinetic of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother 1998; 42:404-8.
137. Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995; 57:662-9.
138. Itraconazole. Med Lett Drugs Ther 1993; 35:7-9.
139. Tucker RM, Haq Y, Denning DW, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990; 26:561-6.
140. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001; 357:1766-77.
141. MacKenzie-Wood AR, Whitfield MJ, Ray JE. Itraconazole and HIV protease inhibitors: an important interaction. Med J Aust 1999; 170: 46-7.
142. Leather HL, Wingard JR. Characterizing the pharmacokinetic drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporine in allogeneic bone marrow transplant patients [abstract A-33]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
143. Barone JA, Moskovitz BL, Guarnieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998; 42:1862-5.
144. Stevens DA. Itraconazole in cyclodextrin solution. Pharmacotherapy 1999; 19:603-11.
145. Hostetler JS, Hanson LH, Stevens DA. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother 1992; 36:477-80.
146. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 1997; 86: 147-62.
147. Slain D, Rogers PD, Cleary JD, Chapman SW Intravenous itraconazole. Ann Pharmacother 2001; 35:720-9.
148. Boogaerts M, Maertens J. Clinical experience with itraconazole in systemic fungal infections. Drugs 2001; 61:39-47.
149. Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001; 33:e83-90.
150. Chiller TM, Stevens DA. Treatment strategies for Aspergillus infections. Drug Resist Updat 2000; 3:89-97.
151. Potter M. European experience with oral and intravenous itraconazole. Oncology 2001; 15:27-32.
152. Odds FC, Oris M, Dorsselaer PV, Van Gerven F. Activities of an intravenous formulation of itraconazole in experimental disseminated Aspergillus, Candida, and Cryptococcus infections. Antimicrob Agents Chemother 2000; 44:3180-3.
153. Groll AH, Mickiene D, Petraitiene R, et al. Dose escalation pharmacodynamic study of intravenous itraconazole in a persistently neutropenic rabbit model of invasive pulmonary aspergillosis [abstract J-1605]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
154. Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97:135-44.
155. Stevens DA, Lee JY. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch Intern Med 1997; 157:1857-62.
156. Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann Pharmacother 2000; 34:1032-43.
157. Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998; 42:741-5.
158. Espinel-Ingroff A. In vitro fungicidial activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39:954-8.
159. Varanasi NL, Baskaran I, Alangaden GJ, Chandrasekar PH. Novel effect of voriconazole on conidiation and pigmentation of Aspergillus species [abstract J-816]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
160. Goldstein JA, deMorais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4:285-99.
161. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46:2546-53.
162. Ghannoum MA, Kuhn DM. Voriconazole - better chances for patients with invasive mycoses. Eur J Med Res 2002; 7:242-56.
163. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34:563-71.
164. Chiou CC, Groll AH, Walsh TJ. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 2000; 5:120-35.
165. Clancy C, Nguyen N. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis 1998; 17:573-5.
166. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12:40-79.
167. Blummer JL, Yanovitch S, Schlamm H, Romero A. Pharmacokinetics and safety of oral voriconazole in patients at risk of fungal infections: a dose escalation study [abstract A-15]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
168. Denning DW, Griffiths CEM. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 2001; 26:648-53.
169. Lazarus HM, Blummer JL, Yanovich S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002; 42:395-402.
170. Tomaszewski K, Purkins L. Visual effects with voriconazole [abstract A-639]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
171. Tan KKC, Wood N, Weil A. Multiple-dose pharmacokinetics of voriconazole in chronic hepatic impairment [abstract A-16]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
172. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21:240-8.
173. Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002; 46:3091-3.
174. Romero A, Le Pogamp P, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002; 71:226-34.
175. Cuenca-Estrella M, Rodriguez-Tudela JL, Mellado E, Martinez-Suarez JV, Monzon A. Comparison of the in-vitro activity of voriconazole (UK-109, 496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998; 42: 531-3.
176. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998;36: 198-202.
177. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001; 150:101-15.
178. Troke PF, Espinel-Ingroff A, Johnson EM, Schlamm H. Susceptibility of moulds from two open, randomised, comparative studies of the efficacy and safety of voriconazole vs. amphotericin B in the treatment of acute invasive aspergillosis in immunocompromised patients [abstract J-820]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
179. Abraham OC, Manavathu EK, Cutright JL, Chandrasekar PH. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Diagn Microbiol Infect Dis 1999; 33:7-11.
180. Verweij PE, Te Dorsthorst DTA, Rijs AJMM, De Vries-Hospers HG, Meis JFGM. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J Clin Microbiol 2002; 40:2648-50.
181. Verweij PE, Mensink M, Rijs AJMM, Donnelly P, Meis JFGM, Denning DW. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother 1998; 42:389-92.
182. Iwen PC, Rupp ME, Langnas AN, Reed EC, Hinrichs SH. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin Infect Dis 1998; 26:1092-7.
183. Sutton DA, Sanchie SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999; 37:2343-5.
184. Espinel-Ingroff A, Johnson E, Troke P. Activity of voriconazole, itraconazole and amphotericin B in vitro against 577 molds from the voriconazole phase III clinical studies [abstract M-1518]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
185. Murphy M, Bernard EM, Ishimaru T, Armstrong D. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1997; 41:696-8.
186. Sugar AM, Liu XP. Effect of grapefruit juice on serum voriconazole concentrations in the mouse. Med Mycol 2000; 38:209-12.
187. Sugar A, Liu XP. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob Agents Chemother 2001; 45: 601-4.
188. Kirkpatrick WR, McAtee RK, Fothergill AW, Rinaldi MG, Patterson TF. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 2000; 44:2865-8.
189. Chandrasekar PH, Cutright J, Manavathu E. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. J Antimicrob Chemother 2000; 45:673-6.
190. George D, Miniter P, Andriole VT. Efficacy of UK-109,496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 1996; 40:86-91.
191. Martin MV, Yates J, Hitchcock CA. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 1997; 41:13-6.
192. Zhou L, Glickman RD, Chen N, Sponsel WE, Graybill JR, Kwok-Wai L. Determination of voriconazole in aqueous humor by liquid chromatography-electrospray ionization-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 776:213-20.
193. Hwang YK, Joo NH, Tee GY, Tan P, Tan L, Girija R. Clinical activity of the new triazole drug voriconazole (UK 109, 496) against disseminated hepatosplenic aspergillosis in a patient with relapse leukemia. Haematologia (Budap) 2001; 31:73-80.
194. Machetti M, Zotti M, Veroni L, et al. Antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole. Transpl Infect Dis 2000; 2:140-4.
195. Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukemia. Br J Haematol 1997; 97:663-5.
196. Swift AC, Denning DW. Skull base osteitis following fungal sinusitis. J Laryngol Otol 1998; 112:92-7.
197. de Sevaux R, Kullberg B, Verweij P, van de Nes J, Meis J, van der Meer J. Microgranulomatous aspergillosis in a patient with chronic granulomatous disease: cure with voriconazole. Clin Infect Dis 1998; 26:996-7.
198. van't Hek LG, Verweij PE, Weemaes CM, van Dalen R, Yntema JB, Meis JFGM. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Respir Crit Care Med 1998; 157:1694-6.
199. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
200. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of Zygomycetes. Antimicrob Agents Chemother 2002; 46:1581-2.
201. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994; 57:1044-50.
202. Steinbach WJ. Combination and sequential antifungal therapy for invasive aspergillosis: review of all published in vitro and in vivo, and clinical antifungal treatment [abstract 8]. In: Program and abstracts of the Focus on Fungal Infections 12 (Phoenix). Alpharetta, GA: Imedex, 2002.
203. Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH. A comparative study of in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 2000; 46:229-34.
204. Marco F, Pfaller MA, Messer SA, Jones RN. In vitro activity of a new triazole antifungal agent, SCH56592, against clinical isolates of filamentous fungi. Mycopathologia 1998; 141:73-7.
205. Cacciapuoti A, Loebenberg D, Corcoran E, et al. In vitro and in vivo activities of SCH 56592 (Posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 2000; 44:2017-22.
206. Uchida K, Yokota N, Yamaguchi H. In vitro antifungal activity of posaconazole against various pathogenic fungi. Int J Antimicrob Agents 2001; 18:167-72.
207. Hayette MP, Amadore A, Seidel L, et al. Comparative in vitro activity of amphotericin B, itraconazole, voriconazole and posaconazole against Aspergillus fumigatus [abstract J-819]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
208. Espinel-Ingroff A, Rezusta A. E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method. J Clin Microbiol 2002; 40:2101-7.
209. Espinel-Ingroff A, Bartlett M, Chaturvedi V, et al. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. Antimicrob Agents Chemother 2001; 45:1828-35.
210. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36:2950-6.
211. Manavathu EK, Abraham OC, Chandrasekar PH. Isolation and in vitro susceptibility to amphotericin B, itraconazole, and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus. Clin Microbiol Infect 2001; 7:130-7.
212. Mellado E, Cuenca-Estrella M, Diaz-Guerra TM. Clinical isolates of Aspergillus fumigatus with a 14-alfa sterol demethylase (cyp51A) point mutation showed in vitro cross-resistance to itraconazole and posaconazole [abstract M-218]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
213. Mann PA, Wei S, Walker SS, et al. Mutations that result in reduced susceptibility to posaconazole in Aspergillus fumigatus appear to be restricted to a single amino acid in CYP51A [abstract M-219]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
214. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. Antimicrob Agents Chemother 2002; 46:1032-7.
215. Espinel-Ingroff A, Fothergill A, Peter J, Rinaldi MG, Walsh TJ. Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol 2002; 40:3204-8.
216. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Antifungal activity of caspofungin and the new triazoles compared with itraconazole and amphotericin B against 462 recent clinical isolates of Aspergillus and other filamentous fungi [abstract M-1521]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
217. Tortorano AM, Dannaoui E, Meletiadis J, et al. Effect of medium composition on static and cidal activity of amphotericin B, itraconazole, voriconazole, posaconazole, and terbinafine against Aspergillus fumigatus: a multicenter study. J Chemother 2002; 14:246-52.
218. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001; 45:857-69.
219. Kirkpatrick WR, McAtee RK, Fothergill AW, Loebenberg D, Rinaldi MG, Patterson TF. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44:780-2.
220. Oakley KL, Morrissey G, Denning DW. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41:1504-7.
221. Graybill JR, Bocanegra R, Najvar LK, Luther MF, Loebenberg D. SCH56592 treatment of murine invasive aspergillosis. J Antimicrob Chemother 1998; 42:539-42.
222. Ezzet F, Wexler D, Courtney R, et al. The pharmacokinetics of posaconazole in neutropenic oncology patients [abstract A-26]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
223. Courtney RD, Statkevich P, Laughlin M, et al. Potential for a drug interaction between posaconazole and phenytoin [abstract A-28]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
224. Hachem RY, Raad II, Afif CM, et al. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections refractory to or intolerant to standard therapy [abstract 1109]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000.
225. Moore CB, Walls CM, Denning DW. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob Agents Chemother 2000; 44:441-3.
226. Arikan S, Rex JH. Ravuconazole Eisai/Bristol-Meyers Squibb. Curr Opin Investig Drugs 2002; 3:555-61.
227. Olsen SJ, Mummaneni V, Rolan P, Norton J, Grasela DM. Ravuconazole single ascending oral dose study in healthy subjects [abstract 838]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000.
228. Grasela DM, Olsen SJ, Mummaneni V, et al. Ravuconazole multiple ascending oral dose study in healthy subjects [abstract 839]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000.
229. Mummaneni V, Geraldes M, Hadjilambris OW, Ouyang Z, Uderman H, Marino MR. Effect of ravuconazole on the pharmacokinetics of simvastatin in healthy subjects [abstract 841]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000.
230. Mummaneni V, Hadjilambris OW, Nichola P, Yan J, Salahudeen I, Marino M. Ravuconazole does not affect the pharmacokinetics of nelfinavir [abstract A-25]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
231. Fung-Tomc JC, Huczko E, Minassian B, Bonner DP. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob Agents Chemother 1998;42:313-8.
232. Espinel-Ingroff A. Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole. Antimicrob Agents Chemother 2001; 45:605-7.
233. Cuenca-Estrella M, Mellado E, Gomez-Lopez A, Monzon A, Rodriguez-Tudela JL. Activity in vitro of ravuconazole against Spanish clinical isolates of yeasts and filamentous fungi [abstract M-1514]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
234. Hata K, Kimura J, Miki H, Toyosawa T, Moriyama M, Katsu K. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1996; 40:2243-7.
235. Mikamo H, Yin XH, Hayasaki Y, et al. Penetration of ravuconazole, a new triazole antifungal, into rat tissues. Chemotherapy 2002; 48: 7-9.
236. Hata K, Kimura J, Miki H, Toyosawa T, Nakamura T, Katsu K. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob Agents Chemother 1996; 40:2237-42.
237. Kirkpatrick W, Perea S, Coco B, Patterson T. Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. J Antimicrob Chemother 2002; 49:353-7.
238. Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44:3381-8.
239. Petraitis V, Petraitiene R, Lyman CA, et al. Efficacy of ravuconazole in treatment of invasive pulmonary aspergillosis in persistently neutropenic rabbits [abstract J-1611]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
240. Chiller T, Farrokhshad K, Brummer E, Stevens DA. Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus. Antimicrob Agents Chemother 2000; 44:3302-5.
241. Groll AH, Gullick BM, Petraitiene R, et al. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob Agents Chemother 2001; 45:596-600.
242. Stone JA, Holland SD, Wickersham PJ, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46:739-45.
243. Hajdu R, Thompson R, Sundelof JG, et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41:2339-44.
244. Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1997; 41:2333-8.
245. Stone EA, Fung HB, Kirschenbaum HL. Caspofungin: an echinocandin antifungal agent. Clin Ther 2002; 24:351-77.
246. Hoang A. Caspofungin acetate: an antifungal agent. Am J Health Syst Pharm 2001; 58:1206-14.
247. Sable CA, Nguyen BYT, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002; 4:25-30.
248. Stone J, Holland S, Li S, et al. Effect of hepatic insufficiency on the pharmacokinetics of caspofungin [abstract A-14]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
249. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics of caspofungin in pediatric patients [abstract M-896]. In: Program and abstracts of the 42nd Interscience Conference on AntimicrobialAgents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
250. Keating GM, Jarvis B. Caspofungin. Drugs 2001; 61:1121-9.
251. Huang A, Edwards F, Bernard EM, Armstrong D, Schmitt HJ. In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) against Aspergillus and Candida species. Eur J Clin Microbiol Infect Dis 1990; 9:697-9.
252. Sutton DA, Rinaldi MG, Fothergill AW. In vitro activity of the echinocandin caspofungin (MK-0991) against refractory clinical isolates of Candida and Aspergillus species [abstract J-113]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
253. Chiller T, Farrokhshad K, Brummer E, Stevens DA. The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagn Microbiol Infect Dis 2001; 39:99-103.
254. Arikan S, Paetznick V, Rex JH. Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2002; 46:3084-7.
255. Bowman JC, Hicks S, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46:3001-12.
256. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug deposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46:12-23.
257. Abruzzo GK, Gill CJ, Flattery AM, et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 2000; 44:2310-8.
258. Bowman JC, Abruzzo GK, Anderson JW, et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001; 45:3474-81.
259. Maertens J, Raad I, Sable C, et al. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin, amphotericin B lipid formulations, or azoles [abstract J-1103]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000.
260. Maertens J, Raad I, Petrikkos G, et al. Update on the multicenter noncomparative study of caspofungin in adults with invasive aspergillosis refractory or intolerant to other antifungal agents: analysis of 90 patients [abstract M-868]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
261. Sanz-Rodriguez C, Aguado JM, Cisneros JM, Vivancos R, Gonzalez-Esteban J. Caspofungin therapy in documented fungal infections: Spanish experience before licensure of the drug [abstract M-895]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
262. Mikamo H, Sato Y, Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother 2000; 46:485-7.
263. Hatano K, Morishita Y, Nakai T, Ikeda F. Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J Antibiot (Tokyo) 2002; 55:219-22.
264. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44:57-62.
265. Groll AH, Mickiene D, Petraitis V, et al. Compartimental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 2001; 45:3322-7.
266. Uchida K, Nishiyama Y, Yokota N, Yamaguchi H. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiot (Tokyo) 2000; 53:1175-81.
267. Tomishima M, Ohki H, Yamada A, et al. FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. J Antibiot (Tokyo) 1999; 52:674-6.
268. Shinoda T, Kume H, Fukushima K, et al. Report of the standardization committee of the Japanese Society of Medical Mycology, 1995-1997 [in Japanese]. Nippon Ishinkin Gakkai Zasshi 1999; 40:239-57.
269. Nakai T, Uno J, Otomo K, et al. In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important moulds. Chemotherapy 2002; 48:78-81.
270. Arikan S, Yurdakul P, Hascelik G. Comparison of two methods and three endpoints in determination of in vitro activity of micafungin against Aspergillus [abstract M-1490]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
271. Stevens DA. Susceptibility to micafungin of isolates from clinical trials [abstract M-1520]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
272. Nakai T, Hatano K, Ikeda F. Electron microscopic findings for micafungin-treated pulmonary aspergillosis in mice [abstract M-1511]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
273. Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46:1857-69.
274. Ikeda F, Wakai Y, Matsumoto S, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 2000; 44: 614-8.
275. Matsumoto S, Wakai Y, Nakai T, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother 2000; 44:619-21.
276. Capilla Luque J, Clemons KV, Stevens DA. Efficacy of FK463 alone and in combination against systemic murine aspergillosis [abstract J-1834]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
277. Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis [abstract 10]. In: Program and abstracts of the Focus on Fungal Infections 12 (Phoenix). Alpharetta, GA: Imedex, 2002.
278. Powles R, Sirohi B, Chopra R, Russel N, Prentice HG. Assessment of maximum tolerated dose of FK463 in cancer patients undergoing haematopoietic stem cell transplantation [abstract J-676]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
279. Kohno S, Masaoka T, Yamaguchi H. A multicenter, open-label clinical study of FK463 in patients with deep mycoses in Japan [abstract J-834]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
280. Ratanatharathorn V, Flynn P, Van Burik JA, McSweeney P, Niederwieser D, Kontoyannis D. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis in bone marrow transplant patients [abstract 2472]. In: Program and abstracts of the American Society of Hematology 44th annual meeting (Philadelphia). Washington, DC: American Society of Hematology, 2002.
281. Zhanel GG, Karlowsky JA, Harding GA, et al. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother 1997; 41: 863-5.
282. Lucas R, De Sante K, Hatcher B, et al. LY303366 single dose pharmacokinetics and safety in healthy volunteers [abstract F-50]. In: Program and abstracts of the 36th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996.
283. Petraitis V, Petraitiene R, Groll AH, et al. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998; 42:2898-905.
284. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30:251-5.
285. Brummer E, Chauhan SD, Stevens D. Collaboration of human phagocytes with LY303366 for antifungal activity against Aspergillus fumigatus. J Antimicrob Chemother 1999; 43:491-6.
286. Groll AH, Mickiene D, Petraitiene R, et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001; 45:2845-55.
287. Verweij PE, Oakley KL, Morrissey J, Morrissey G, Denning DW. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother 1998; 42:873-8.
288. Clemons KV, Sobel RA, Stevens DA. Toxicity of LY303366, an echinocandin antifungal, in mice pretreated with glucocorticoids. Antimicrob Agents Chemother 2000; 44:378-81.
289. Thye D, Shepherd B, White RJ, Weston IE, Henkel T. Anidulafungin: a phase 1 study to identify the maximum tolerated dose in healthy volunteers [abstract A-36]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
290. Thye D, Kilfoil T, White RJ, Lasseter K. Anidulafungin: pharmacokinetics in subjects with mild and moderate hepatic impairment [abstract A-34]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
291. Harrari S. Current strategies in the treatment of invasive Aspergillus infections in immunocompromised patients. Drugs 1999; 58:621-31.
292. Balfour JA, Faulds D. Terbinafine, a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992; 43:259-84.
293. Kovarik JM, Kirkessell S, Humbert H, Grass P, Kutz K. Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers. Br J Dermatol 1992; 126:8-13.
294. Jensen JC. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol 1989; 14:110-3.
295. Conjeevaram G, Vongthavaravat V, Sumner R, Koff R. Terbinafine-induced hepatitis and pancytopenia. Dig Dis Sci 2001; 46:1714-6.
296. Anania FA, Rabin L. Terbinafine hepatotoxicity resulting in chronic biliary ductopenia and portal fibrosis. Am J Med 2002; 112:741-2.
297. Aguilar C, Mueller KK. Reversible agranulocytosis associated with oral terbinafine in a pediatric patient. J Am Acad Dermatol 2001; 45:632-4.
298. Richert B, Uhoda I, De la Brassinne M. Hair loss after terbinafine treatment [letter]. Br J Dermatol 2001; 145:842.
299. Teitelbaum ML, Pearson VE. Imipramine toxicity and terbinafine [letter]. Am J Psychiatry 2001; 158:2086.
300. O'Reardon JP, Hetznecker JM, Rynn MA, Baldassano CF, Szuba MP. Desipramine toxicity with terbinafine [letter]. Am J Psychiatry 2002; 159:492.
301. Hosseini-Yeganeh M, McLachlan AJ. Physiologically based pharmacokinetic model for terbinafine in rats and humans. Antimicrob Agents Chemother 2002; 46:2219-28.
302. Kovarik JM, Mueller EA, Zehender H, Denouel J, Caplain H, Millerioux L. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Antimicrob Agents Chemother 1995; 39:2738-41.
303. Hosseini-Yeganeh M, McLachlan AJ. Tissue distribution of terbinafine in rats. J Pharm Sci 2001; 90:1817-28.
304. Hosseini-Yeganeh M, McLachlan AJ. In-vitro distribution of terbinafine in rat and human blood. J Pharm Pharmacol 2002; 54:277-81.
305. Ryder NS. Activity of terbinafine against serious fungal pathogens. Mycoses 1999; 42:115-9.
306. Schmitt HJ, Bernard EM, Andrade J, Edwards F, Schmitt B, Armstrong D. MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 1988; 32:780-1.
307. Jessup CJ, Ryder NS, Ghannoum MA. An evaluation of the in vitro activity of terbinafine. Med Mycol 2000; 38:155-9.
308. Moore CB, Walls CM, Denning DW. In vitro activities of terbinafine against Aspergillus species in comparison with those of itraconazole and amphotericin B. Antimicrob Agents Chemother 2001; 45:1882-5.
309. Verweij PE, van Den Bergh MFQ, Rath PM, de Pauw BE, Voss A, Meis JFGM. Invasive aspergillosis caused by Aspergillus ustus: case report and review. J Clin Microbiol 1999; 37:1606-9.
310. Schmitt HJ, Andrade J, Edwards F, Niki Y, Bernard E, Armstrong D. Inactivity of terbinafine in a rat model of pulmonary aspergillosis. Eur J Clin Microbiol Infect Dis 1990; 9:832-5.
311. Ryder NS, Frank I. Interaction of terbinafine with human serum and serum proteins. J Med Vet Mycol 1992; 30:451-60.
312. Hay RJ. Therapeutic potential of terbinafine in subcutaneous and systemic mycoses. Br J Dermatol 1999; 141:36-40.
313. Denning DW. Invasive aspergillosis in immunocompromised patients. Curr Opin Infect Dis 1994; 7:456-62.
314. Schaffner A, Douglas H, Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus: observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J Clin Invest 1982; 69:617-31.
315. Schneemann M, Schaffner A. Host defense mechanism in Aspergillus fumigatus infections. Contrib Microbiol 1999; 2:57-68.
316. Schaffner A. Macrophage-Aspergillus interactions. Immunol Ser 1994; 60:545-52.
317. Dixon DM, Polak A, Walsh TJ. Fungus dose-dependent primary pulmonary aspergillosis in immunosuppressed mice. Infect Immun 1989; 57:1452-6.
318. Cenci E, Perito S, Enssle KH, et al. Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immun 1997; 65:564-70.
319. Rodriguez-Adrian LJ, Grazziutti ML, Rex JH, Anaissie EJ. The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis 1998; 26:1270-8.
320. Roilides E, Pizzo PA. Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. Clin Infect Dis 1992; 15:508-24.
321. Palmer LB, Greenberg HE, Schiff M. Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease. Thorax 1991; 46:15-20.
322. Roilides E, Blake C, Holmes A, Pizzo PA, Walsh TJ. Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J Med Vet Mycol 1996; 34:63-9.
323. Diamond RD. Inhibition of monocyte-mediated damage to fungal hyphae by steroid hormones. J Infect Dis 1983; 147:160.
324. Duong M, Ouellet N, Simard M, Bergeron Y, Olivier M, Bergeron MG. Kinetic study of host defense and inflammatory response to Aspergillus fumigatus in steroid-induced immunosuppressed mice. J Infect Dis 1998; 178:1472-82.
325. Graybill JR, Bocanegra R, Najvar LK, Loebenberg D, Luther MF. Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Antimicrob Agents Chemother 1998; 42:2467-73.
326. Ng TTC, Robson GD, Denning DW. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 1994; 140:2475-9.
327. Berenguer J, Allende MC, Lee JW, et al. Pathogenesis of pulmonary aspergillosis. Am J Respir Crit Care Med 1995; 152:1079-86.
328. Hamilton JA, Whitty GA, Royston AKM, Cebon J, Layton JE. Interleukin-4 suppresses granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in stimulated monocytes. Immunology 1992; 76:566-71.
329. Saxena S, Bhatnagar PK, Ghosh PC, Sarma PU. Effect of amphotericin B lipid formulation on immune response in aspergillosis. Int J Pharm 1999; 188:19-30.
330. Cenci E, Mencacci A, Fe d'Ostiani C, et al. Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis 1998; 178:1750-60.
331. Cenci E, Mencacci A, Del Sero G, et al. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I response. J Infect Dis 1999; 180:1957-68.
332. Casadevall A, Pirofski LA. Adjunctive immune therapy for fungal infections. Clin Infect Dis 2001; 33:1048-56.
333. Clemens KV, Grunig G, Sobel RA, Mirels F, Rennick DM, Stevens DA. Role of IL-10 in invasive aspergillosis: increased resistance of IL-10 gene knockout mice to lethal systemic aspergillosis. Clin Exp Immunol 2000; 122:186-91.
334. Roilides E, Dimitriadou A, Kadiltsoglou I, et al. IL-10 exerts suppressive and enhancing effects on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Immunol 1997; 158:322-9.
335. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996; 88:1907-29.
336. Hartung T. Anti-inflammatory effects of granulocyte colony-stimulating factor. Curr Opin Hematol 1998; 5:221-5.
337. Hartung T. Granulocyte colony-stimulating factor: its potential role in infectious disease. AIDS 1999; 13:S3-9.
338. Polak-Wyss A. Protective effect of human granulocyte colony-stimulating factor (hG-CSF) on Cryptococcus and Aspergillus infections in normal and immunosuppressed mice. Mycoses 1991; 34:205-15.
339. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993; 61:4870-7.
340. Liles WC, Huang JE, van Burik JH, Bowden RA, Dale DC. Granulocyte colony-stimulating factor administered in vivo augments neutrophilmediated activity against opportunistic fungal pathogens. J Infect Dis 1997; 175:1012-5.
341. Geller RB. Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J Clin Oncol 1996; 14:1371-82.
342. Roilides E, Holmes A, Blake C, Venzon D, Pizzo PA, Walsh TJ. Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony stimulating factor and interferon-gamma. J Infect Dis 1994; 170: 894-9.
343. Nemunaitis J. Use of macrophage colony-stimulating factor in the treatment of fungal infections. Clin Infect Dis 1998; 26:1279-81.
344. Gamble JR, Rand TH, Lopez AF, Clark-Lewis I, Vadas MA. Heterogeneity of recombinant granulocyte-macrophage colony-stimulating factor-mediated enhancement of neutrophil adherence to endothelium. Exp Hematol 1990; 18:897-902.
345. Khatami S, Brummer E, Stevens DA. Effects of granulocyte-macrophage colony stimulating factor (GM-CSF) in vivo on cytokine production and proliferation by spleen cells. Clin Exp Immunol 2001; 125:198-201.
346. Brummer E, Maqbool A, Stevens DA. In vivo GM-CSF prevents dexamethasone suppression of killing of Aspergillus fumigatus conidia by bronchoalveolar macrophages. J Leukoc Biol 2001; 70:868-72.
347. Brummer E, Maqbool A, Stevens DA. Protection of bronchoalveolar macrophages by granulocyte-macrophage colony-stimulating factor against dexamethasone suppression of fungicidal activity for Aspergillus fumigatus conidia. Med Mycol 2001; 39:509-15.
348. Brummer E, Maqbool A, Stevens DA. Protection of peritoneal macrophages by granulocyte/macrophage colony-stimulating factor (GM-CSF) against dexamethasone suppression of killing of Aspergillus, and the effect of human GM-CSF. Microbes and Infection 2002; 4:133-8.
349. Bodey GP. The potential role of granulocyte-macrophage colony stimulating factor in therapy of fungal infections: a commentary. Eur J Clin Microbiol Infect Dis 1994; 13:363-6.
350. Abu Jawdeh L, Haidar R, Bitar F, et al. Aspergillus vertebral osteomyelitis in a child with a primary monocyte killing defect: response to GM-CSF therapy. J Infect 2000; 41:97-100.
351. Boots RJ, Paterson DL, Allworth AM, Faoagali JL. Successful treatment of post-influenza pseudomembranous necrotising bronchial aspergillosis with liposomal amphotericin, inhaled amphotericin B, gamma interferon, and GM-CSF. Thorax 1999; 54:1047-9.
352. Rowe JM, Andersen JW, Maza J, et al. A randomized, placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86:457-62.
353. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S. Role of granulocyte macrophage colony-stimulating factor as adjuvant therapy for fungal infections in patients with cancer. Clin Infect Dis 1993; 17:705-7.
354. Groll A, Renz S, Gerein V, et al. Fatal haemoptysis associated with invasive pulmonary aspergillosis treated with high-dose amphotericin B and granulocyte-macrophage colony-stimulating factor (GM-CSF). Mycoses 1992; 35:67-75.
355. Albelda SM, Talbot GH, Gerson ST, Miller WT, Cassileth PA. Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis. Influence of bone marrow recovery in patients with acute leukemia. Am Rev Respir Dis 1985; 131:115-20.
356. Roilides E, Dignani MC, Anaissie EJ, Rex JH. The role of immunoreconstitution in the management of refractory opportunistic fungal infections. Med Mycol 1998; 36:12-25.
357. Roilides E, Sein T, Holmes A, et al. Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Infect Dis 1995; 172:1028-34.
358. Gonzalez CE, Lyman CA, Lee S, et al. Recombinant human macrophage colony-stimulating factor augments pulmonary host defences against Aspergillus fumigatus. Cytokine 2001; 15:87-95.
359. Nemunaitis J, Meyers JD, Buckner CD, et al. Phase I trial of recombinant human macrophage colony-stimulating factor (rhM-CSF) in patients with invasive fungal infections. Blood 1991; 78:907-13.
360. Laichalk LL, Kunkel SL, Strieter RM, Danforth JM, Bailie MB, Standiford TJ. Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia. Infect Immun 1996; 64:5211-8.
361. Mehrad B, Strieter RM, Standiford TJ. Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis. J Immunol 1999; 162:1633-40.
362. Roilides E, Dimitriadou-Georgiadu A, Sein T, Kadiltsoglou I, Walsh TJ. Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus. Infect Immun 1998; 66:5999-6003.
363. Schelenz S, Smith DA, Bancroft GJ. Cytokine and chemokine responses following pulmonary challenge with Aspergillus fumigatus: obligatory role of TNF-alpha and GM-CSF in neutrophil recruitment. Med Mycol 1999; 37:183-94.
364. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993; 61:1185-93.
365. Vora S, Chauhan S, Brummer E, Stevens DA. Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother 1998; 42:2299-303.
366. Nagai H, Guo J, Choi H, Kurup V. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J Infect Dis 1995; 172:1554-60.
367. Gaviria JM, van Burik JH, Dale DC, Root RK, Liles WC. Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. J Infect Dis 1999; 179:1038-41.
368. Winn RM, Maloukou A, Gil-Lamaignere C, Panteliadis C, Roilides E. Interferon-gamma (IFN) and granulocyte-macrophage colony stimulating factor (GM-CSF) enhance hyphal damage of Aspergillus and Fusarium spp. by human neutrophils (PMN) [abstract J-134]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
369. Rex JH, Bennett J, Gallin JI, Malech HL, DeCarlo ES, Melnick DA. In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis 1991; 163:849-52.
370. Rex JH, Bennett JE, Gallin JI, Malech HL, Melnick DA. Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J Infect Dis 1990; 162:523-9.
371. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of Interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991; 324:509-16.
372. Saulsbury FT. Successful treatment of Aspergillus brain abscess with itraconazole and interferon-gamma in a patient with chronic granulomatous disease. Clin Infect Dis 2001; 32:e137-9.
373. Bernhisel-Broadbent J, Camargo EE, Jaffe HS, Lederman HM. Recombinant human interferon-gamma as adjunct therapy for Aspergillus infection in a patient with chronic granulomatous disease. J Infect Dis 1991; 163:908-11.
374. Ellis M, Watson R, McNabb A, Lukic ML, Nork M. Massive intracerebral aspergillosis responding to combination high dose liposomal amphotericin B and cytokine therapy without surgery. J Med Microbiol 2002; 51:70-5.
375. Stevens DA. Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis 1998; 26:1266-9.
376. Stevens DA, Kullberg B, Brummer E, Casadevall A, Netea MG, Sugar AM. Combined treatment: antifungal drugs with antibodies, cytokines or drugs. Med Mycol 2000; 38:305-15.
377. Menzel F Jr, Jackson C, Patera A, et al. Combination treatment of posaconazole and granulocyte colony-stimulating factor against Aspergillus in a mouse pulmonary infection model [abstract M-858]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
378. Strumia MM. The effect of leukocyte cream injections in the treatment of the neutropenia. Am J Med Sci 1934; 187:527-44.
379. Emmendorffer A, Lohmann-Matthes ML, Roesler J. Kinetics of transfused neutrophils in peripheral blood and BAL fluid of a patient with variant X-linked chronic granulomatous disease. Eur J Haematol 1991; 47:246-52.
380. Stroncek DF, Leonard K, Eiber G, Malech HL, Gallin JI, Leitman SF. Alloimmunization after granulocyte transfusions. Transfusion 1996; 36:1009-15.
381. Berliner S, Weinberger M, Ben-Bassat M, et al. Amphotericin B causes aggregation of neutrophils and enhances pulmonary leukostasis. Am Rev Respir Dis 1985; 132:602-5.
382. Swerdlow B, Deresinski S. Development of Aspergillus sinusitis in a patient receiving amphotericin B. Am J Med 1984; 76:162-6.
383. Ozsahin H, von Planta M, Muller I, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin B. Blood 1998; 92:2719-24.
384. Bielori B, Toren A, Wolach B, et al. Successful treatment of invasive aspergulosis in chronic granulomatous disease by granulocyte transfusions followed by peripheral blood stem cell transplantation. Bone Marrow Transplant 2000; 26:1025-8.
385. Catalano L, Fontana R, Scarpato N, Picardi M, Rocco S, Rotoli B. Combined treatment with amphotericin-B and granulocyte transfusion from G-CSF-stimulated donors in an aplastic patient with invasive aspergulosis undergoing bone marrow transplantation. Haematologica 1997; 82:71-2.
386. Dignani MC, Anaissie EJ, Hester JP, et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997; 11:1621-30.
387. Peters C, Minkov M, Matthes-Martin S, et al. Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients. Br J Haematol 1999; 106:689-96.
388. Bhatia S, McCullough J, Perry EH, Clay M, Ramsay NKC, Neglin JP. Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation. Transfusion 1994; 34:226-32.
389. Hubel K, Carter RA, Liles WC, et al. Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion 2002; 42:1414-21.
390. Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 1995; 39:1907-12.
391. Nemunaitis J, Shannon-Dorcy K, Appelbaum FR, et al. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood 1993; 82:1422-7.